Lubrizol Life Science Health (LLS), a Berkshire Hathaway Company, has introduced its ASTAGILE microcapsules, its new sustainable, organic-certified, astaxanthin (Haematococcus pluvialis), microencapsulated with spirulina, it was reported on Wednesday.
Both ingredients have been combined in a patent-pending product aimed to promote mental agility and support healthy ageing for young and senior adults.
Astaxanthin is a carotenoid found in freshwater microalgae, while spirulina is a type of algae. In order to create the synergistic algae blend, LLS Health collaborated with Neoalgae Micro Seaweeds Products, SL, a research and development company in Spain dedicated to microalgae biotechnology. LLS claims that recent studies showed the cognitive enhancement effects of ASTAGILE, including a boost in memory performance, cognition and learning capabilities, and provided antioxidant and anti-inflammatory protection to the brain.
Genflow Biosciences publishes second European patent application for SIRT6 Variant in NASH
Trellus Health signs contract with leading global CRO and expands clinical trial offerings
GSK reports positive Phase III data for low-carbon version of Ventolin inhaler
Terns Pharmaceuticals reports topline 12-week data from Phase 2 trial of TERN-601 in obesity
The Los Angeles Trust for Children's Health Appoints Dr Sarah Rodman as New Executive Director
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Genentech's Gazyva (obinutuzumab) receives US FDA approval to treat adults with lupus nephritis
ACG to invest USD200m in US hard-shell capsule manufacturing
Charles River and X-Chem form strategic collaboration to accelerate hit identification
Merck reports long-term survival benefits of Keytruda in non-small cell lung cancer
Avacta reports promising Phase 1a data for faridoxorubicin at ESMO 2025
AstraZeneca wins US FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps
Faron Pharmaceuticals reports stronger bexmarilimab data at ESMO 2025